Azilect patents expiration

AZILECT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 TEVA Rasagiline formulations and processes for their preparation
Dec, 2026

(3 years from now)

Azilect is owned by Teva.

Azilect contains Rasagiline Mesylate.

Azilect has a total of 2 drug patents out of which 0 drug patents have expired.

Azilect was authorised for market use on 16 May, 2006.

Azilect is available in tablet;oral dosage forms.

Azilect can be used as treatment of parkinson's disease.

The generics of Azilect are possible to be released after 27 August, 2027.

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease


More Information on Dosage

AZILECT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic